Home
Deepak 's Library tagged → View Popular
22 Jan 07
Alliances Key Ingredient in Novartis Pipeline Plan :: Bio-IT World
-
evin, who was CEO of Physiome (an early in silico company) before joining NIBR, said Novartis maintains “a rich interest in in silico biology.” Many of the key modelers on his former Physiome team have joined Novartis, which is also collaborating with Entelos.
-
Licensing deals totaled $13.5 billion last year, with increasing focus on early-stage compounds. But Levin observed that over the past 18 months, most of his potential partnering conversations have taken a turn, ending in, “Would you like to buy us?”
Selected Tags
Related Tags
pharma (29)- marketresearch (10)
- industryinfo (9)
- drugdevelopment (5)
- healthcare (5)
- industry (4)
- fda (4)
- bioit (4)
- bioinformatics (4)
- industryorganization (4)
- lifescience (3)
- business (3)
- clinical (3)
- personalizedmedicine (3)
- topsellingdrugs (3)
- genomics (2)
- novartis (2)
- trends (2)
- regulatory (2)
- policy (2)
Sponsored Links
Ads by Google
Top Contributors
Groups interested in Pharma
Diigo is about better ways to research, share and collaborate on information. Learn more »
Join Diigo